Skip to main content
HHS Logo U.S. Department of Health & Human Services NIH logo National Institutes of Health

Discovering New Therapeutic Uses for Existing Molecules

This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses. Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically.
NCATS Seeks Applications to Repurpose Existing Drugs to Advance COVID-19 Research

NCATS seeks applications for projects that repurpose existing drugs to address the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, coronavirus disease 2019 (COVID-19).

Crystal McKnight examines a compound source plate.
Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)

This urgent funding opportunity announcement invites applications to repurpose existing therapeutic agents to treat COVID-19 sequelae and associated complications that result from SARS-CoV-2 infections.

Work with Us

Learn more about how you can access funding and collaborate with the New Therapeutic Uses program.

Bobbie Ann Mount, Ph.D.

New Therapeutic Uses Facts

Therapeutic development is a costly, complex and time consuming process. The average length of time from target discovery to approval of a new drug is about 14 years. The failure rate during this process exceeds 95 percent, and the cost per successful drug can be $1 billion or more. The high therapeutic development failure rate means there are many existing, partially developed therapeutic candidates that could be repurposed for use in new disease indications.Learn more about the New Therapeutic Uses program through the fact sheet (PDF - 395KB).